Table 6.

Demographic and clinical characteristics for the different genotypes of rs10733113 in UC patients

	rs10733113 GG	rs10733113 AG	rs10733113 AA	p value (Fisher or Kruskal–Wallis)
Gender
Male (n = 369)  Female (n = 321)	276 (53.5%) 240 (46.5%)	10 (71.4%) 4 (28.6%)	83 (51.9%) 77 (48.1%)	0.392
Age at diagnosis [years]
Median, q25–q75,  Min–max	27.7, 19.8–38.7, 2.9–79.6	38.0, 27.1–40.8, 19.5–63.2	29.2, 19.7–36.7, 3.4–69.4	0.099
Disease duration [years]
Median, q25–q75,  Min–max	11.1, 6.7–18.4, 0.2–49.5	10.7, 7.8–17.8, 2.9–26.3	11.7, 7.3–18.8, 0.5–40.1	0.619
Complications*
No (n = 286)  Yes (n = 404)	225 (43.6%) 291 (56.4%)	6 (42.9%) 8 (57.1%)	55 (34.4%) 105 (65.6%)	0.122
MTWAI–maximal value throughout follow-up
Median, q25–q75,  Min–max	4, 2–8.5, 0–19	7.5, 3–9, 0–13	5, 2–9, 0–17	0.704
Reported flare*  No (n = 284)  Yes (n = 406)	213 (41.3%) 303 (58.7%)	7 (50.0%) 7 (50.0%)	64 (40.0%) 96 (60.0%)	0.753
Flare possibly or highly related to (focus on yes):
NSAIDs  Antibiotics  GI tract infection  Other infection  Treatment decr. / disc  Other medication	19 (6.3%) 6 (2.0%) 51 (16.8%) 29 (9.6%) 74 (24.4%) 9 (3.0%)	0 (0%) 1 (14.3%) 1 (14.3%) 0 (0%) 2 (28.6%) 0 (0%)	4 (4.2%) 1 (1.0%) 22 (22.9%) 10 (10.4%) 22 (22.9%) 5 (5.2%)	0.746 0.150 0.347 0.924 0.864 0.484
Flare management (focus on the yes):
Hospitalization  Ambulatory  Surgery  Drug therapy	39 (12.9%) 89 (29.4%) 16 (5.3%) 271 (89.4%)	0 (0%) 1 (14.3%) 0 (0%) 7 (100%)	7 (7.3%) 14 (14.6%) 3 (3.1%) 90 (93.8%)	0.278 0.008 0.702 0.367
Focus on the hospitalizations:
Total days of hosp.  Median, q25–q75,  Min–max	4, 0–16, 0–90	–	0, 0–3, 0–12	0.063

Bold indicates a significant p-value (p < 0.05)